Expanded Access to VAL-083

NCT03138629 | Unknown

• 1 other identifier: DLM-17-002
• Study Type: expanded_access
• Target: N/A
• Locations: 0 countries
• Sites: N/A

Brief Summary

This is an expanded access program (EAP) for eligible participants. This program is designed to provide access to VAL-083 (dianhydrogalactitol) prior to approval by the local regulatory agency. Availability will depend on territory eligibility. Participating sites will be added as they apply for and are approved for the EAP. A medical doctor must decide whether the potential benefit outweighs the risk of receiving an investigational therapy based on the individual patient's medical history and program eligibility criteria.

Conditions

Cancer

Interventions

VAL-083 DRUG

VAL-083 will be administered intravenously

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Patient has relapsed/refractory disease and exhausted all standard treatments.

You may not qualify if:

• Patient is eligible for a VAL-083 clinical trial.
• Patient has previously received VAL-083 for the same disease.

Sponsors & Collaborators

• Kintara Therapeutics, Inc.: lead

MeSH Terms

Conditions

Neoplasms

Study Design

• Study Type: expanded access
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: May 1, 2017
• First Posted: May 3, 2017
• Last Updated: November 22, 2023

Record last verified: 2023-11